Sutro Biopharma (STRO) Receivables - Net (2017 - 2025)

Sutro Biopharma's Receivables - Net history runs 9 years deep, the most recent figure standing at $4.0 million for Q4 2025.

• In Q4 2025, Receivables - Net fell 53.84% year-over-year to $4.0 million; the TTM figure through Dec 2025 stood at $4.0 million (down 53.84% YoY), while the FY2025 annual figure was $4.0 million, down 53.84% from the prior year.
• Receivables - Net came in at $4.0 million for Q4 2025 at Sutro Biopharma, up from $3.9 million in the prior quarter.
• In the past five years, Receivables - Net ranged from a high of $97.7 million in Q2 2022 to a low of $3.9 million in Q3 2025.
• A 5-year average of $16.2 million and a median of $9.9 million in 2023 frame the typical range for Receivables - Net.
• Across the five-year window, Receivables - Net surged 966.28% in 2022 and sank 89.76% in 2023, its largest moves.
• Sutro Biopharma's Receivables - Net stood at $12.5 million in 2021, then sank by 42.81% to $7.1 million in 2022, then jumped by 406.57% to $36.1 million in 2023, then plunged by 76.12% to $8.6 million in 2024, then tumbled by 53.84% to $4.0 million in 2025.
• According to Business Quant data, Receivables - Net over the past three periods registered $4.0 million, $3.9 million, and $8.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.

Peer Comparison